Department of Neurology, The People's Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China.
Department of Gynecology, The People's Hospital of Beilun District, Beilun Branch Hospital of The First Affiliated Hospital, Zhejiang University School of Medicine, Ningbo, Zhejiang Province, China.
Braz J Med Biol Res. 2021 Mar 15;54(5):e10000. doi: 10.1590/1414-431X202010000. eCollection 2021.
This study aimed to explore the effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction. A total of 120 patients with acute cerebral infarction were divided into two groups by the random number table method, with 60 patients in each group: observation group (intravenous thrombolysis with alteplase) and control group (intravenous thrombolysis with batroxobin). The clinical efficacy after a 14-day treatment was observed. Serum C-reactive protein (CRP), tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), CD62p, GMP-140, and neuron-specific enolase (NSE) were measured. Scores of National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA) were determined. The total effective rate in the observation group was 81.67%, which was higher than the 61.67% in the control group (P<0.05). The improvement of inflammatory factors (CRP, TNF-α, IL-6, CD62p, GMP-140, and NSE), NIHSS, MMSE, and MoCA in the observation group was superior to that in the control group (all P<0.05). The modified Rankin scale at three months after hospital discharge in the observation group was lower than that in the control group (P<0.01). Intravenous thrombolysis with alteplase for acute cerebral infarction can enhance the clinical efficacy, alleviate inflammatory response and brain injury, and improve cognitive function, which is worthy of further clinical application and study.
本研究旨在探讨阿替普酶静脉溶栓对急性脑梗死患者临床疗效、炎症因子及神经功能的影响。将 120 例急性脑梗死患者采用随机数字表法分为两组，每组 60 例：观察组（阿替普酶静脉溶栓）和对照组（巴曲酶静脉溶栓），观察两组患者治疗 14 天后的临床疗效，检测血清 C 反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、CD62p、血栓调节蛋白（GMP-140）、神经元特异性烯醇化酶（NSE），并测定美国国立卫生研究院卒中量表（NIHSS）、简易精神状态检查量表（MMSE）、蒙特利尔认知评估量表（MoCA）评分，统计两组患者的总有效率。观察组总有效率为 81.67%，高于对照组的 61.67%（P<0.05）。观察组 CRP、TNF-α、IL-6、CD62p、GMP-140、NSE 等炎症因子及 NIHSS、MMSE、MoCA 评分改善情况优于对照组（均 P<0.05）。观察组出院后 3 个月改良 Rankin 量表评分低于对照组（P<0.01）。阿替普酶静脉溶栓治疗急性脑梗死可提高临床疗效，减轻炎症反应和脑损伤，改善认知功能，值得进一步临床应用和研究。
